of genes involved in cell cycle regulation, DNA repair and apoptosis [1] . Thus, p53 allows DNA repair (ER ϭ 7.0,. Negative oestrogen and progesterone receptor (ER/PR) status was positively associated with both p53 protein overexpression (ϭ 2.6, 
that of other cancers, with less G:C to T:A transversions and more A:T to G:C transitions. Variations have been observed in the pattern of p53 mutations in breast cancer by geographical location and may reflect the effect of environmental factors and/or ethnicity. A higher frequency of G:C to A:T transitions and G:C to T:A transversions was observed among breast cancer cases in Western countries
, suggesting exposure to tobacco smoke [2] . Deletions were more frequent in breast cancers cases from Japan [2] . There are also differences in the mutation pattern by ethnicity, with a significantly higher frequency of all types of transitions among African-American women than among Caucasians. The reason for this difference is not known, but it is hypothesized that population-specific environmental exposure or endogenous factors may play a role [4] .
Immunohistochemical staining of p53 provides information on the expression of the protein and has become a widely used method of mutant p53 detection. The correlation between p53 mutations and p53 protein overexpression is estimated to be less than 75% for breast cancer [5] . This discrepancy is attributed to the fact that not all mutations result in stable protein formation; also, some tumours may express increased levels of wild-type p53. However, there is also some uncertainty regarding the methodological aspects of p53 immunohistochemical detection that may be responsible for the differences in the frequency of p53 mutations and p53 protein levels [6] . [7] [8] [9] . In contrast, studies that use sequencing to detect p53 mutations generally have demonstrated shorter survival with the presence of mutations [10, 11] [12] .
Although detection of p53 overexpression by immunohistochemistry has been done to investigate its association with survival for a number of different cancers, the results are inconclusive
In the present study, we investigated the frequency and type of p53 mutation in exons [5] [6] [7] [8] 
Materials and methods

Study population
The details of the LIBCSP case-control [13] and the follow-up cohort [14] [15, 16] . The majority of case interviews occurred prior to the initiation of chemotherapy or radiation therapy. [17] . The method has been successfully used in various applications, including detection of heteroplasmic mitochondrial DNA mutations [21] , detection of mutations in the hCDC4 gene in patients with acute myeloid leukaemia [22] and p53 mutations in exons 5-8 in patients with haematological malignancies [23] . Owing to the decreasing costs of sequencing, future studies will not be required to utilise this pre-screening method because it is no longer cost-effective. [24] [25] [26] [27] [28] [29] . Immunohistochemical staining is widely used; however, the method is semiquantitative and subjective and the results may depend on the threshold set during scoring. Moreover, a recent study [30] reported that the results could be strongly affected by the concentration of antibody used for staining, even reversing observed relationships.
Medical records and archived tumour tissue at baseline
Follow-up data
p53 mutations classification
The mutations in p53 were classified according to type (point mutations, including transitions and transversions, and insertions or deletions) or their effect (missense, nonsense, silent and frameshift/in-frame mutations). Missense mutations were further split into mutations within the DNA-binding domains (DBD) and mutations within non-DBD [11]. DBD mutations included mutations in the L2 and L3 loops (codons 164-194 and 237-250, respectively) and in the LSH motif (codons 119-135 and 272-285). These codons are in contact with
Table 2 Odds ratios (OR) and 95% confidence intervals (CIs) for the association between p53 mutation status and protein p53 overexpression assessed by immunohistochemistry among the LIBCSP case participants who were diagnosed with a first primary breast cancer in 1996-1997
Table 3 Odds ratios (OR) and 95% confidence intervals (CI) for the association between any p53 mutation and p53 overexpression assessed by immunohistochemistry and ER/PR status and tumour stage among the LIBCSP case participants who were diagnosed with breast cancer in 1996-
Immunohistochemical staining for p53 protein provides information on the concentration and localisation of the protein. In our study, we detected p53 overexpression in 36% of tumour samples. This frequency is comparable with other studies that reported positive p53 immunostaining in 30-40% of samples
However, in our study, we observed a significant association between p53 mutations and p53 protein overexpression even if various cut-points for determination of p53 positive staining were used. A further analysis revealed that missense mutations were responsible for this association, whereas nonsense, silent and frameshift/in-frame mutations had no effect on immunohistochemistry results. A significant correlation between p53 overexpression and p53 mutations was observed by others [24, 31, 32] , although some authors report no correlation between these two parameters [33, 34] .
ER/PR status is an important molecular marker of breast tumours with both prognostic and predictive functions [12, 35] . ER/PR-positive tumours are usually better differentiated and have better prognosis and survival rate [36] . We observed a significant association between ER/PR-negative status and p53 protein overexpression, which is consistent with the results of at least one [37, 38] , but not all other, studies. We assume that any discrepancy across studies may be caused by the reported variability of the p53 immunohistochemistry assay [30] .
We observed a borderline difference in p53 protein overexpression between in situ and invasive breast cancer, thus confirming the results of others [24] . Some studies, however, did not find any difference [25, 26, 39] . The study of Warnberg et al. suggests that p53 expression reflects grade rather than invasiveness of the disease [39] .
The association of p53 mutation status with other clinical and tumour characteristics including ER/PR status has been observed in a number of studies [40] [41] [42] [43] [44] 
. Similar to these results, our study found women with ER/PR-negative tumours had almost a fourfold higher risk of having p53 mutations than women carrying ER/PR-positive tumours.
Mutations in p53 are correlated with higher histological grade of a tumour [41, 42] . It has been shown that mutations occur in ductal carcinoma in situ before the development of invasive breast cancer, and that their frequency increases with higher grade of the disease [45] . Although p53 mutations are more frequent in advanced breast carcinoma [33, 46, 47] [10, 11, 26, [41] [42] [43] [44] 49] and reported that the presence of p53 mutations was associated with poorer survival, although most are based on small case series of breast cancer patients (which yield unstable results). From these studies, only two were population-based [26, 49] , and two were adjusted to hormone receptor status [42, 43] . In our large population-based sample, however, once adjustments were made for ER/PR status, there was no effect of mutations on survival. To our knowledge, only two studies larger than ours have been published on the prognostic value of p53 mutations in breast cancer [11, 42] [10, 35, 51] . Some studies, including ours, reported no relationship with breast cancer survival [38, 52, 53] , whereas other authors found a significant decrease in survival associated with p53 expression [54] [55] [56] .
In our study, we analysed p53 mutations only in exons 5-8, which is sufficient due to the fact that these exons contain Ͼ90% of the mutations reported in breast cancer [11] . Although our sample size was smaller than that in the two previously mentioned studies which used p53 mutation analysis, our study has several advantages. First, unlike the study by Olivier et al. [11] 
